Supernus Pharmaceuticals annual debt-to-ebitda ratio
2018
2019
2020
2021
2022
2023
2024
2025
Supernus Pharmaceuticals Debt-to-EBITDA Ratio Growth & History (SUPN)
Supernus Pharmaceuticals's debt-to-ebitda ratio was 1.40 for fiscal 2025.
View full Supernus Pharmaceuticals company overviewSupernus Pharmaceuticals annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.40 | 1.19 | +561.87% |
| 2024 | 2024-12-31 | 0.21 | −0.31 | −59.47% |
| 2023 | 2023-12-31 | 0.52 | −2.86 | −84.55% |
| 2022 | 2022-12-31 | 3.38 | −0.22 | −6.17% |
| 2021 | 2021-12-31 | 3.60 | 3.31 | +1125.86% |
| 2020 | 2020-12-31 | 0.29 | 0.08 | +37.03% |
| 2019 | 2019-12-31 | 0.21 | 0.21 | — |
| 2018 | 2018-12-31 | 0.00 | — | — |
Supernus Pharmaceuticals quarterly debt-to-ebitda ratio
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | 1.11 | 0.90 | +429.76% |
| Q4 2025 | 2025-12-31 | 1.40 | 1.19 | +561.87% |
| Q3 2025 | 2025-09-30 | 0.98 | 0.72 | +272.02% |
| Q2 2025 | 2025-06-30 | 0.22 | −0.14 | −38.46% |
| Q1 2025 | 2025-03-31 | 0.21 | −0.38 | −64.58% |
| Q4 2024 | 2024-12-31 | 0.21 | −0.31 | −59.47% |
| Q3 2024 | 2024-09-30 | 0.26 | −0.11 | −28.43% |
| Q2 2024 | 2024-06-30 | 0.36 | −0.04 | −10.76% |
| Q1 2024 | 2024-03-31 | 0.59 | −2.74 | −82.28% |
| Q4 2023 | 2023-12-31 | 0.52 | −2.86 | −84.55% |
| Q3 2023 | 2023-09-30 | 0.37 | −6.42 | −94.56% |
| Q2 2023 | 2023-06-30 | 0.40 | −4.08 | −91.03% |
| Q1 2023 | 2023-03-31 | 3.33 | 2.95 | +783.59% |
| Q4 2022 | 2022-12-31 | 3.38 | −0.22 | −6.17% |
| Q3 2022 | 2022-09-30 | 6.79 | 6.49 | +2194.48% |
| Q2 2022 | 2022-06-30 | 4.48 | 4.23 | +1706.07% |
| Q1 2022 | 2022-03-31 | 0.38 | 0.07 | +21.85% |
| Q4 2021 | 2021-12-31 | 3.60 | 3.31 | +1125.86% |
| Q3 2021 | 2021-09-30 | 0.30 | −0.02 | −5.87% |
| Q2 2021 | 2021-06-30 | 0.25 | −0.10 | −28.59% |
| Q1 2021 | 2021-03-31 | 0.31 | 0.09 | +43.42% |
| Q4 2020 | 2020-12-31 | 0.29 | 0.08 | +37.03% |
| Q3 2020 | 2020-09-30 | 0.31 | 0.12 | +59.54% |
| Q2 2020 | 2020-06-30 | 0.35 | 0.14 | +71.16% |
| Q1 2020 | 2020-03-31 | 0.22 | 0.00 | +0.99% |
| Q4 2019 | 2019-12-31 | 0.21 | 0.21 | — |
| Q3 2019 | 2019-09-30 | 0.20 | — | — |
| Q2 2019 | 2019-06-30 | 0.20 | — | — |
| Q1 2019 | 2019-03-31 | 0.21 | — | — |
| Q4 2018 | 2018-12-31 | 0.00 | — | — |
Supernus Pharmaceuticals debt-to-ebitda ratio trends
Over the last five fiscal years, Supernus Pharmaceuticals's debt-to-ebitda ratio increased from 0.29 to 1.40, a change of 1.11. The latest reported quarter, Q1 2026, shows 1.11.
About the metric
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
Calculation and source
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Supernus Pharmaceuticals source filings ↗Community posts
Supernus and Indivior report sales growth ahead of their expected merger closing
Supernus ($SUPN) reported third-quarter 2026 revenue of $226.8 million, up 18%, with Qelbree sales increasing 12% to $90.8 million and Onapgo contributing $17.1 million. Separately, merger partner Indivior ($INDV) posted revenue of $356 mil ...
Supernus confirms ONAPGO exclusivity and seeks a second supplier
Supernus ($SUPN) said the FDA has recognized orphan-drug exclusivity for ONAPGO, its apomorphine infusion treatment for motor fluctuations in adults with advanced Parkinson's disease. The seven-year protection period runs from the medicine' ...
